IMPACT THERAP-B (07630) and METIS TECHBIO-P (07666) are currently in their public offering phases. As of May 6, brokerages including Futu Securities and Phillip Securities have provided HKD 7.495 billion in margin financing for IMPACT THERAP-B, representing an oversubscription of more than 82.09 times. For METIS TECHBIO-P, they have provided HKD 51.132 billion in margin financing, representing an oversubscription of more than 483.99 times.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments